From a retrospective analysis of GEPs from AML patients and healthy donors, we show that patient AML samples display increased levels of FADS1 mRNA compared to healthy donors and that elevated FADS1 expression correlates with worse outcomes. Here, FADS1 is linked to acute myeloid leukemia.